Year: 2017
Type: article
Abstract: Reg Harris There has been a resurgence of interest in the concept of decentralised manufacturing (DCM) of health products including some cell and gene therapies (CGTs).The relative merits of traditional, essentially centralised, manufacturing and delivery of CGTs and the decentralised alternative(s) have been at the heart of the debate.A significant driver of activity is the growing call from the marketplace for efficacious, safe and personalised therapies.
Authors: Reg Harris, Richard P. Harrison
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2766464354